Evidence map›Paper›PMID 35836901›Full record

ArticleAmerican journal of translational research2022

Metronidazole-loaded nanoparticulate thermoreversible gel for gynecologic infection of

Ling Fang, Xianyi Lu, Chengjun Cui, Qifeng Shi, Haojue Wang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ling FangDepartment of Dermatology, Xishan People's Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University Wuxi 214105, Jiangsu, China.
Xianyi LuDepartment of Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University Wuxi 214105, Jiangsu, China.
Chengjun CuiDepartment of Dermatology, Xishan People's Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University Wuxi 214105, Jiangsu, China.
Qifeng ShiDepartment of Pathology, Xishan People's Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University Wuxi 214105, Jiangsu, China.
Haojue WangDepartment of Obstetrics and Gynecology, Xishan People's Hospital of Wuxi City, Wuxi Branch of Zhongda Hospital Southeast University Wuxi 214105, Jiangsu, China.
Wuxi No.2 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTrichomoniasis is a common sexually-transmitted disease that is associated with increased perinatal morbidity and human immunodeficiency virus (HIV) transmission. This study aimed to develop a Metronidazole-loaded nanoparticulate thermoreversible gel for gynecological infection of

methodsThe optimized nanoparticulate formulation was used in thermoreversible gel and characterized for physico-chemical properties, antiparasitic activity, and

resultA nearly threefold rise in antiparasitic activity of the optimized formulation was observed as compared to that of regular gel. Formulation F5 successfully cured the trichomoniasis within 3 days, while regular gel and pure Metronidazole (MTDZ) failed to cure this infection (P<0.05).

conclusionThe present investigation confirms the ability of thermoreversible gel containing nanoparticulate metronidazole againstthe infection by

Indexed as

chitosandrug deliveryMetronidazolenanoparticlespoloxamerthermoreversibleTrichomonas vaginalistrichomoniasisvaginal

Identifiers

PMID35836901
PMCPMC9274572
OpenAlexW4285611164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.